Cargando…

(89)Zr Immuno-PET Imaging of Tumor PD-1 Reveals That PMA Upregulates Lymphoma PD-1 through NFκB and JNK Signaling

Immune therapy of T-cell lymphoma requires assessment of tumor-expressed programmed cell death protein-1 (PD-1). Herein, we developed an immuno-PET technique that quantitatively images and monitors regulation of PD-1 expression on T-cell lymphomas. Methods. Anti-PD-1 IgG underwent sulfhydryl moiety-...

Descripción completa

Detalles Bibliográficos
Autores principales:	Jung, Kyung-Ho, Lee, Jin Hee, Kim, Mina, Cho, Young Seok, Lee, Kyung-Han
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Hindawi 2022
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8865856/ https://www.ncbi.nlm.nih.gov/pubmed/35250391 http://dx.doi.org/10.1155/2022/5916692

Ejemplares similares

Potential and pitfalls of (89)Zr-immuno-PET to assess target status: (89)Zr-trastuzumab as an example
por: Huisman, Marc C., et al.
Publicado: (2021)

A novel [(89)Zr]-anti-PD-1-PET-CT to assess response to PD-1/PD-L1 blockade in lung cancer
por: Puyalto, Ander, et al.
Publicado: (2023)

Celecoxib-Induced Modulation of Colon Cancer CD133 Expression Occurs through AKT Inhibition and Is Monitored by (89)Zr Immuno-PET
por: Jung, Kyung-Ho, et al.
Publicado: (2022)

Evaluation of (89)Zr-Labeled Anti-PD-L1 Monoclonal Antibodies Using DFO and Novel HOPO Analogues as Chelating Agents for Immuno-PET
por: Radaram, Bhasker, et al.
Publicado: (2023)

Cysteine-specific (89)Zr-labeled anti-CD25 IgG allows immuno-PET imaging of interleukin-2 receptor-α on T cell lymphomas
por: Lee, Jin Hee, et al.
Publicado: (2022)

PD-L1 detection using (89)Zr-atezolizumab immuno-PET in renal cell carcinoma tumorgrafts from a patient with favorable nivolumab response
por: Vento, Joseph, et al.
Publicado: (2019)

Toward Optimized (89)Zr-Immuno-PET: Side-by-Side Comparison of [(89)Zr]Zr-DFO-, [(89)Zr]Zr-3,4,3-(LI-1,2-HOPO)- and [(89)Zr]Zr-DFO*-Cetuximab for Tumor Imaging: Which Chelator Is the Most Suitable?
por: Damerow, Helen, et al.
Publicado: (2022)

Imaging the L-Type Amino Acid Transporter-1 (LAT1) with Zr-89 ImmunoPET
por: Ikotun, Oluwatayo F., et al.
Publicado: (2013)

Imaging PD-L1 Expression with ImmunoPET
por: Truillet, Charles, et al.
Publicado: (2017)

(89)Zr-Immuno-Positron Emission Tomography in Oncology: State-of-the-Art (89)Zr Radiochemistry
por: Heskamp, Sandra, et al.
Publicado: (2017)

(89)Zr-immuno-PET using the anti-LAG-3 tracer [(89)Zr]Zr-BI 754111: demonstrating target specific binding in NSCLC and HNSCC
por: Miedema, Iris H.C., et al.
Publicado: (2023)

(89)Zr-Labeled AR20.5: A MUC1-Targeting ImmunoPET Probe
por: Fung, Kimberly, et al.
Publicado: (2020)

(89)Zr-nimotuzumab for immunoPET imaging of epidermal growth factor receptor I
por: Chekol, Rufael, et al.
Publicado: (2018)

(89)Zr-pembrolizumab biodistribution is influenced by PD-1-mediated uptake in lymphoid organs
por: van der Veen, Elly L, et al.
Publicado: (2020)

(89)Zr anti-CD44 immuno-PET monitors CD44 expression on splenic myeloid cells and HT29 colon cancer cells
por: Park, Jin Won, et al.
Publicado: (2021)

Zr-89 Immuno-PET Targeting Ectopic ATP Synthase Enables In-Vivo Imaging of Tumor Angiogenesis
por: Park, Bok-Nam, et al.
Publicado: (2019)

Immuno-PET Imaging of Atherosclerotic Plaques with [(89)Zr]Zr-Anti-CD40 mAb—Proof of Concept
por: Poels, Kikkie, et al.
Publicado: (2022)

Cerebral rituximab uptake in multiple sclerosis: A (89)Zr-immunoPET pilot study
por: Hagens, Marloes HJ, et al.
Publicado: (2017)

Interobserver reproducibility of tumor uptake quantification with (89)Zr-immuno-PET: a multicenter analysis
por: Jauw, Yvonne W. S., et al.
Publicado: (2019)

Direct comparison of the in vitro and in vivo stability of DFO, DFO* and DFOcyclo* for (89)Zr-immunoPET
por: Raavé, René, et al.
Publicado: (2019)

Tumor-Specific Zr-89 Immuno-PET Imaging in a Human Bladder Cancer Model
por: Escorcia, Freddy E., et al.
Publicado: (2018)

Noise sensitivity of (89)Zr-Immuno-PET radiomics based on count-reduced clinical images
por: Somasundaram, Ananthi, et al.
Publicado: (2022)

Current Perspectives on (89)Zr-PET Imaging
por: Yoon, Joon-Kee, et al.
Publicado: (2020)

(89)Zr-DFO-Isatuximab for CD38-Targeted ImmunoPET Imaging of Multiple Myeloma and Lymphomas
por: Herrero Alvarez, Natalia, et al.
Publicado: (2023)

Immuno-PET Imaging of the Programmed Cell Death-1 Ligand (PD-L1) Using a Zirconium-89 Labeled Therapeutic Antibody, Avelumab
por: Jagoda, Elaine M., et al.
Publicado: (2019)

Immuno-PET Imaging of Tumour PD-L1 Expression in Glioblastoma
por: Sharma, Gitanjali, et al.
Publicado: (2023)

Optimisation of scan duration and image quality in oncological (89)Zr immunoPET imaging using the Biograph Vision PET/CT
por: van Sluis, Joyce, et al.
Publicado: (2023)

Additional information on “Direct comparison of the in vitro and in vivo stability of DFO, DFO* and DFOcyclo* for (89)Zr-immunoPET”
por: Raavé, René, et al.
Publicado: (2019)

Head-to-head comparison of DFO* and DFO chelators: selection of the best candidate for clinical (89)Zr-immuno-PET
por: Chomet, Marion, et al.
Publicado: (2020)

Comparative in vivo biodistribution of cells labelled with [(89)Zr]Zr-(oxinate)(4) or [(89)Zr]Zr-DFO-NCS using PET
por: Friberger, Ida, et al.
Publicado: (2023)

First-in-human immunoPET imaging of HIV-1 infection using (89)Zr-labeled VRC01 broadly neutralizing antibody
por: Beckford-Vera, Denis R., et al.
Publicado: (2022)

Improved image reconstruction of (89)Zr-immunoPET studies using a Bayesian penalized likelihood reconstruction algorithm
por: Kirchner, Julian, et al.
Publicado: (2021)

Preclinical PET imaging with the novel human antibody (89)Zr-DFO-REGN3504 sensitively detects PD-L1 expression in tumors and normal tissues
por: Kelly, Marcus P, et al.
Publicado: (2021)

Molecular Interactions of Antibody Drugs Targeting PD-1, PD-L1, and CTLA-4 in Immuno-Oncology
por: Lee, Hyun Tae, et al.
Publicado: (2019)

The PD-1/PD-L1 Pathway: A Perspective on Comparative Immuno-Oncology
por: Schöniger, Sandra, et al.
Publicado: (2022)

ImmunoPET: IMaging of cancer imMUNOtherapy targets with positron Emission Tomography: a phase 0/1 study characterising PD-L1 with (89)Zr-durvalumab (MEDI4736) PET/CT in stage III NSCLC patients receiving chemoradiation study protocol
por: Hegi-Johnson, Fiona, et al.
Publicado: (2022)

Optimal imaging time points considering accuracy and precision of Patlak linearization for (89)Zr-immuno-PET: a simulation study
por: Wijngaarden, Jessica E., et al.
Publicado: (2022)

Advancing (89)Zr-immuno-PET in neuroscience with a bispecific anti-amyloid-beta monoclonal antibody - The choice of chelator is essential
por: Wuensche, Thomas E., et al.
Publicado: (2022)

Development of (89)Zr-Ontuxizumab for in vivo TEM-1/endosialin PET applications
por: Lange, Sara E.S., et al.
Publicado: (2016)

[89Zr]-immuno-PET prediction of response to rituximab treatment in patients with therapy refractory interstitial pneumonitis: a phase 2 trial
por: Adams, H., et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_p7phgpr7p0bu9oeh0fcjb9bf6r